Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp. -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (183)	2/5/2009 11:11:31 AM
From: nigel bates	Respond to of 197

Dyax Announces Expansion of Antibody Discovery Collaboration with Biogen Idec Thursday February 5, 10:45 am ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX - News) announced today that they have expanded their antibody funded research and library license agreement with Biogen Idec (NASDAQ:BIIB - News) to include the discovery of additional antibody products identified using Dyax’s proprietary drug discovery technology, phage display. Dyax has utilized phage display to generate on behalf of Biogen Idec high affinity, fully human antibody product candidates, including BIIB-022, currently in Phase 1 clinical trials for oncology, and one additional product candidate targeting LINGO-1 for multiple sclerosis moving into the clinic. Under the terms of the expanded agreement, Dyax has guaranteed a minimum of ten additional product licenses to Biogen Idec. Additionally, Dyax has granted Biogen Idec a non-exclusive license to its antibody libraries and will conduct antibody discovery funded research over a three-year period. In exchange, Dyax will receive a $5 million upfront fee and guaranteed research funding, and is eligible to receive $85 million in development and sales milestones as well as royalties for each antibody product commercialized by Biogen Idec using Dyax’s technology. “Biogen Idec is a leader in the development and commercialization of innovative therapies, and this agreement reflects how Dyax’s phage display technology has become an increasingly important and validated drug discovery platform,” remarked Gustav A. Christensen, President and CEO of Dyax Corp. “We look forward to continuing our collaboration with Biogen Idec generating value for both companies through the discovery of innovative therapeutic antibodies.”